– FDA approval based on the phase 3 CABINET pivotal trial, which demonstrated a statistically significant and clinically meaningful improvement in progression-free survival versus placebo ...

Exelixis, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved CABOMETYX® (cabozantinib) for the treatment of 1) adult and pediatric patients 12 years of age and older ...

What initially seems like purely psychological trouble may indeed have roots in physical conditions that, once identified, ...

Various factors can trigger flushing, including emotions such as embarrassment, high temperatures, alcohol intake, or specific medical conditions like carcinoid syndrome. A statement on the NHS ...

“The characteristics of NET vary widely from patient to patient, and very few treatment options have demonstrated the ability to improve outcomes across such a heterogeneous population,” said Jennifer ...

Feb. 6, 2025 — Scientists have created a new low-cost, fast response sensor to detect lung cancer biomarkers, paving the way for the development of screening devices to spot the disease even ...

Rutgers Health researchers have discovered that networks of misplaced immune cells drive an aggressive lung disease, ...

Neuroendocrine tumors that start in the pancreas tend to be more aggressive and have a poor prognosis.

Mar. 25, 2025 — Researchers have found a potential new way to slow the progression of lung fibrosis and other fibrotic diseases by inhibiting the expression or function of Piezo2, a receptor ...

The COVID-19 pandemic engulfed the U.S. five years ago this month, leaving not only lingering mental health effects but also long-term physical symptoms. One of those included a condition known as ...